Biotech News

PepGen Announces Pricing of $125 Million Public Offering

PepGen (PEPG)PepGenFinancing

BOSTON --(BUSINESS WIRE)--Nov. 11, 2026-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies with the potential to transform the treatment of rare genetic diseases, today announced the pricing of a public offering of 25,000,000 shares of its

Related news

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

Stock data

Close
3.93 USD
Market cap
100.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States